Tularemia

01/01/2014 - "Thus, liposomal ciprofloxacin is a promising treatment for tularemia and further research with the aim of enabling licensure under the animal rule is warranted. "
01/01/2001 - "The efficacy of ciprofloxacin treatment of tularemia in children is also discussed."
04/01/2015 - "Ciprofloxacin: Tularemia (Adults)."
01/01/2014 - "tularensis live vaccine strain, showed that a single dose of liposomal ciprofloxacin given by the intranasal or inhalational route could provide protection in a mouse model of pneumonic tularemia. "
04/01/2013 - "Ciprofloxacin is an effective and convenient choice in epidemics of tularemia and early treatment is still the cornerstone of successful therapies."

07/01/2011 - "The results of our study suggest that streptomycin is an effective choice of first-line treatment for pediatric oropharyngeal tularemia patients."
03/01/2012 - "We believe that streptomycin should be the first-line antibiotic in the treatment of pediatric tularemia cases, but it should be supported by comprehensive studies with larger patient series."
09/01/1971 - "[Study of the immunizing effect of the virulent Tularemia strain treated by streptomycin]."
07/01/1949 - "Streptomycin studies in tularemia; streptomycin therapy in monkeys."
07/01/1949 - "Streptomycin studies in tularemia; streptomycin therapy in white rats."

08/27/2009 - "These results demonstrate the efficacy of an epitope-based tularemia vaccine and suggest that such an approach might be widely applicable to the development of vaccines specific for intracellular bacterial pathogens."
03/31/2005 - "Further, understanding of how inhaled LVS elicits local cell-mediated protective immunity will be critical for devising improved vaccines against pulmonary tularemia."
09/08/2003 - "In order to begin understanding the immunological basis for immunity to tularemia, and to establish a baseline for judging the efficacy of potential novel vaccines, the present study examined the ability of the live vaccine strain of Francisella tularensis (F. "
01/01/2014 - "Currently, there are no licensed vaccines and no correlates of protection against Francisella tularensis, which causes tularemia. "
01/01/2008 - "For study of the effects of whole-body gamma-radiation (1 and 4 Gy) on the response of the body to administration of vaccines and virulent strains of tularemia 206 outbred white mice were used. "

04/20/2007 - "The T lymphocyte antigens, which may have a role in protection against tularemia, were predicted by immunoinformatics analysis of Francisella tularensis Schu4. "
08/01/1990 - "The Francisella tularensis T-lymphocyte antigens, which may have a role in protection against tularemia, were investigated with vaccine-immunized subjects. "
09/01/2011 - "PHR was the most effective study method that allowed to detect tularemia antigen in the environmental objects in high quantities (up to 9.2% of positive samples) and high titers (up to 1:1600). "
10/01/2006 - "Tularemia antigen was annually detected in the study samples. "
06/01/1991 - "tularemia antigen-stimulated PBMC increased 2 weeks after tularemia onset, but the mean number of CD8+ DR+ T lymphocytes did not vary during the study period and no correlation could be found between the soluble CD8 and number of CD8+ DR+ T lymphocytes. "

10/01/1992 - "The combined therapy of tularemia was also considered promising because of its high efficacy when the treatment was started at late periods as well as because unlike the monotherapy with the aminoglycoside antibiotics it provided complete elimination of the pathogen from the host."
03/01/1992 - "Efficacy of antibiotics in the treatment of experimental tularemia was studied comparatively on various biological models. "
08/01/1967 - "[Study of the mechanism of action of antibiotics on the development of immunity in experimental tularemia]."
02/01/1962 - "[Studies on the sensitivity of some types of tularemia pathogen and Pasteurella to antibiotics in vitro]."
01/01/2013 - "All strains were susceptible to the antibiotics traditionally used to treat tularemia. "

08/01/1972 - "Tularemia treated successfully with gentamicin."
01/01/1980 - "Gentamicin was bactericidal for Francisella tularensis in vitro, was effective in mouse tularemia when given in large doses, and was effective in humans when given in the standard recommended dose."
09/01/2013 - "We present a patient with oculoglandular tularemia that did not respond to gentamicin to demonstrate the need for prolonged antimicrobial treatment and surgical intervention."
07/13/2012 - "We found that immunization with MPF significantly increased the effectiveness of subtherapeutic gentamicin for post-exposure treatment of pneumonic tularemia, with 100% of combination-treated mice surviving long-term. "
07/01/2011 - "Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia."

02/01/1983 - "We have described a patient with tularemia who had nonoliguric acute renal failure probably due to interstitial nephritis and who recovered slowly but spontaneously during antimicrobial therapy with doxycycline."
01/01/2005 - "Doxycycline and ciprofloxacin have each been investigated for the treatment of tularemia in outpatients; however, these agents do not yet have established roles in the treatment of this disease in children. "
03/31/2003 - "Diagnosis of tularemia was obtained serologically, and antibiotic therapy with doxycycline and streptomycin resolved symptoms and radiological abnormalities. "
01/01/1989 - "We present a case of ulceroglandular tularemia distinguished by its relapse after initial streptomycin/doxycycline therapy and subsequent slow response to additional streptomycin."
05/01/1985 - "[Experimental multifactorial study of the effect of doxycycline and glucosaminylmuramyl dipeptide on the primary immunologic response to antigens of a tularemia vaccine strain]."

10/30/2003 - "The effect of liposome delivery on the controlled release and therapeutic efficacy of ciprofloxacin against intracellular Francisella tularensis infection in vivo was evaluated in this study. "
06/01/1997 - "Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice."
01/01/2014 - "The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy."
10/30/2003 - "Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection."
11/01/2009 - "Abacavir sulfate/lamivudine, Adalimumab, AdCD40L, Adefovir, Adefovir dipivoxil, Ambrisentan, Amlodipine, Amlodipine besylate/olmesartan medoxomil, AN-2728, Apixaban, Aripiprazole, Armodafinil, Atazanavir sulfate, Atomoxetine hydrochloride, Atrasentan, Azacitidine, Bevacizumab, Blinatumomab, Bortezomib, Bosentan, Carfilzomib, Caspofungin acetate, Cediranib, Cetuximab, Choriogonadotropin alfa, Clevudine, Clindamycin phosphate/benzoyl peroxide, Clofarabine, Daidzeol, Darunavir, Dasatinib, Decitabine, Deferasirox, Deforolimus, Degarelix acetate, Denenicokin, Dexlansoprazole, Duloxetine hydrochloride, Elacytarabine, Enfuvirtide, Enoxaparin, Entecavir, Eribulin mesilate, Erlotinib hydrochloride, Escitalopram oxalate, Eslicarbazepine acetate, Eszopiclone, Etravirine, Ezetimibe/simvastatin, Forodesine hydrochloride, Fosamprenavir calcium, Gefitinib, Gemtuzumab ozogamicin, Golimumab, Imatinib mesylate, Imetelstat, Insulin gl'argine, Insulin glulisine, Interferon alfa-2b XL, Ivabradine hydrochloride, Lacosamide, Lenalidomide, Lintuzumab, Liposomal adriamycin, Liposomal belotecan, Liposome-encapsulated fentanyl, Lopinavir/ritonavir, Lutropin alfa, LY-207320, Maraviroc, Mecasermin, MKC-253, MP-470, NGR-TNF, Nilotinib hydrochloride monohydrate, Ofatumumab, Olmesartan medoxomil, Omacetaxine mepesuccinate, PAN-811, Panobinostat, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/ribavirin, Pemetrexed disodium, Perospirone hydrochloride, PF-734200, Phentermine/topiramate, Pimecrolimus, Pitavastatin calcium, Plerixafor hydrochloride, Pregabalin, Raltegravir potassium, Ramelteon, Ranibizumab, Recombinant Bet V1, Recombinant human insulin, Regadenoson, rhITF, Romidepsin, Rosuvastatin calcium, Ruboxistaurin hydrochloride, Rufinamide, Sapropterin dihydrochloride Saracatinib, SB-73, SC-599, Seliciclib, Sirolimus-eluting stent, Sorafenib, Sunitinib malate, Tadalafil, Tanespimycin, Tapentadol hydrochloride, Tegaserod maleate, Telbivudine, Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate/emtricitabine, Tenofovir disoproxil fumarate/emtricitabine/efavirenz, Ticlopidine hydrochloride, Tigecycline, TST-10088, Tularemia vaccine, Valsartan/amlodipine besylate, Vandetanib, Vardenafil hydrochloride hydrate, Vincristine, Vorinostat, Yttrium 90 (90Y) ibritumomab tiuxetan."

05/01/2006 - "Fluoroquinolones may therefore be considered useful candidates for the treatment of pneumonic tularemia."
10/01/1999 - "Treatment of tularemia with fluoroquinolones: two cases and review."
01/01/2007 - "Comparative in vitro and in vivo efficacy of new fluoroquinolones with respect to pathogens of tularemia, glanders, melioidosis and anthrax was estimated. "
05/01/2013 - "In addition, all isolates except 1 had a minimal inhibitory concentration (MIC) for erythromycin of > 256 μg/ml. Since the fluoroquinolones showed the lowest MIC values and have advantages such as excellent bioavailability and activity, availability of oral formulations, and lower toxicities, they represent candidate therapeutic options in the first-line treatment of tularemia. "
02/01/1991 - "These in vitro and in vivo results show that orally administered fluoroquinolones are promising antimicrobial agents for the treatment of human tularemia."

03/01/1988 - "tularensis agglutinogens and contained a variety of proteins, several of which functioned as immunogens in tularemia patients, as shown by Western blotting (immunoblotting). "
02/01/1995 - "Live tularemia vaccine but not proteins purified from Francisella tularensis can confer protection against lethal Listeria infection in mice."
07/01/2006 - "Six ABC system proteins were evaluated as candidate vaccine antigens against tularemia, although none provided significant protection against F. "

10/01/2012 - "Tularemia in a kidney transplant recipient."
01/01/2006 - "Tularemia in a renal transplant recipient."
05/01/2005 - "Tularemia in a kidney transplant recipient: an unsuspected case and literature review."
01/01/2003 - "We report a case of tularemia in a neutropenic bone marrow transplant recipient that sheds light on the importance of neutrophils in protection against this infection and review clinical aspects of this fascinating infection emphasizing areas of interest for immunocompromised hosts."
05/01/2005 - "Tularemia is a zoonotic infection that has rarely been reported in transplant recipients. "

04/01/2012 - "Superselective neck dissection is a safe and effective option in the treatment of long lasting cervical tularemia unless it responds to medical treatment."

02/06/2015 - "Collectively, this use of orthogonal proteomic approaches reduced the complexity of potential immunogens in MPF by 96% and allowed for prioritization of target immunogens for antibody-based immunotherapies against tularemia. "
11/15/2013 - "This manuscript will review advances made and challenges in the field of immunotherapy against tularemia. "
11/15/2013 - "Immunotherapy for tularemia."
10/15/2007 - "tularensis live vaccine strain (LVS) for potential use as immunotherapy of tularemia. "
11/15/2013 - "tularensis acquiring resistance to antibiotics via natural or illicit means, augmentation of host immunity, and humoral immunotherapy have been investigated as countermeasures against tularemia. "

01/01/2013 - "These results support use of the MglA/SspA interacting surface, and quinacrine's chemical scaffold, for the design of high affinity molecules that will function as therapeutics for the treatment of Tularemia."
01/01/2011 - "Because of concerns that tularemia could be used as a bioterrorism agent, vaccines and therapeutics are urgently needed. "
01/01/2012 - "Development of novel vaccines and therapeutics for tularemia has been hampered by the lack of understanding of which immune components are required to survive infection. "

05/01/2005 - "The authors present a case of unsuspected tularemia in a kidney transplant patient that was diagnosed by isolation of Francisella tularensis in the blood. "
07/01/1999 - "To our knowledge, this is the only reported case of tularemia occurring in the post-transplant setting. "
07/01/1999 - "We report a case of tularemia presenting as a solitary pulmonary nodule following syngeneic PBSC transplant. "
07/01/1999 - "Tularemia--an unusual cause of a solitary pulmonary nodule in the post-transplant setting."